Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
February 10, 2021

Coronavirus company news summary – Grapheal raises $2.30m to advance embedded biosensing technology for Covid-19 testing – ProPhase begins advanced, saliva-based viral PCR multiplex-testing for Covid-19 and other viruses

By Chloe Kent

Grapheal, a developer of graphene-based embedded biosensors, announced that it has raised a total of $2.30m in equity and non-dilutive sources. The funds will be utilised to advance the development of Grapheal’s flexible graphene-based biosensor technology. The sensing technology will serve as a new generation digital Covid-19 test, TestNPass, for rapid screening at airports, as well as a wound care digital assistant, WoundLAB, will improve the monitoring of hard-to-heal wounds.

ProPhase Labs, a medical science and technology company, has started a new saliva-based, viral RT-PCR multiplex-testing as a laboratory developed test (LDT) classification. The company has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for its two new testing solutions. The company has integrated Spectrum Solutions SDNA-1000 Saliva Collection Systems along with an advanced multiplex qPCR platform for the simultaneous detection of the SARS-CoV-2 virus, influenza A & B, and other viral mutations. https://www.globenewswire.com/news-release/2021/02/09/2172248/0/en

Nanomix, a point-of-care diagnostics developer, announced that the company has submitted an EUA to the FDA for the eLab Covid-19 rapid antigen test. The assay runs on the mobile Nanomix eLab analyser, which delivers results within 15 minutes and can be used across hospitals, assisted living facilities, nursing homes, urgent care centres, and emergency medical care.

Related Companies

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU